The company’s new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid outperformed Wall Street forecasts.
Tag Archive for: Reblozyl
BMS pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.
With Celgene and other acquisition costs in the rearview, Bristol Myers Squibb returned to profitability with a vengeance in 2021.
